34 results about "Coronary artery stent" patented technology

A coated implantable medical device 10 includes a structure 12 adapted for introduction into the vascular system, esophagus, trachea, colon, biliary tract, or urinary tract; at least one coating layer 16 posited on one surface of the structure; and at least one layer 18 of a bioactive material posited on at least a portion of the coating layer 16, wherein the coating layer 16 provides for the controlled release of the bioactive material from the coating layer. In addition, at least one porous layer 20 can be posited over the bioactive material layer 18, wherein the porous layer includes a polymer and provides for the controlled release of the bioactive material therethrough. Preferably, the structure 12 is a coronary stent. The porous layer 20 includes a polymer applied preferably by vapor or plasma deposition and provides for a controlled release of the bioactive material. It is particularly preferred that the polymer is a polyamide, parylene or a parylene derivative, which is deposited without solvents, heat or catalysts, and merely by condensation of a monomer vapor.

The invention discloses a cutting process of a coronary artery stent. A specific operation method comprises the following steps: pre-treating a plurality of stent patterns which are the same or have different specifications respectively; carrying out staggered placement on the tail end of a first stent pattern and the front end of a second stent pattern, so as to move the tail end of the first stent pattern into remains, which do not need to be machined, in the front end of the second stent pattern in a staggered manner; reserving process allowance in a laser cutting process, and so on, and placing the third or more stent patterns; generating an NC procedure on host equipment through the plurality of patterns which are arranged in the staggered manner, and cutting a stent pipe through a laser cutting machine; cutting off the process allowance to separate the coronary artery stents. According to the cutting process of the coronary artery stent, the plurality of stent patterns are arranged in the staggered manner and then are machined as a whole body, so that the production efficiency is remarkably improved and the utilization rate of the pipe is greatly improved, and furthermore, a lot of raw materials are saved.

The invention provides a cobalt-based alloy. The cobalt-based alloy includes Cu element, wherein the content of Cu element is 4.5-5.5% by weight. The invention also provides a thermal processing method and a heat treatment method of the cobalt-based alloy; and the application of the cobalt-based alloy as a coronary artery stent. The cobalt-based alloy continuously produces trace amounts of copper in the cardiovascular system, which can not only inhibit the hyperplasia, migration and degeneration of arterial smooth muscle after coronary stent implantation, but also effectively reduce the formation of thrombus, thereby reducing or inhibiting coronary artery stent implantation. Function of in-stent restenosis induced after implantation.

The present invention relates to D-galactopyranose compounds of formula (1) wherein the pyranose ring is beta-D-galactopyranose, these compounds are high affinity galectin-1 and / or-3 inhibitors for use in the treatment of inflammation; thrombosis caused by inflammation; specific dermatitis; acute coronary syndrome; fibrosis, such as pulmonary fibrosis, hepatic fibrosis, renal fibrosis, ocular fibrosis, and fibrosis of the skin and heart; local fibrosis, such as Duput's foot disease and Petroleum disease; fibrosis complications of other therapies such as coronary artery stents, bile duct stents, cerebral artery stents and ureteral stents; scleroderma; scars; scar tumor formation; new coronal pneumonia-19; acute lung injury; an ARDS; viral pneumonia; abnormal scar formation; surgical adhesion; infectious shock; cancers such as colorectal cancer, other gastrointestinal cancers such as pancreatic cancer, gastric cancer, biliary tract cancer, lung cancer, mesothelioma, female cancers such as breast cancer, ovarian cancer, uterine cancer, cervical cancer, fallopian tube cancer, brain cancers such as myeloblastoma, glioma, meningioma, skeletal and muscle sarcoma and other sarcoma, leukemia and lymphoma such as T cell lymphoma; transplant rejection; metastatic cancers; aging; dementia; alzheimer's disease; bone diseases driven by TGF-beta, such as osteogenesis imperfection; pulmonary arterial hypertension; autoimmune diseases, such as psoriasis, rheumatoid arthritis, rheumatoid lung disease; , Crohn's disease, ulcerative colitis, ankylosing spondylitis, systemic lupus erythematosus; viral infections such as influenza virus, HIV, herpes virus, coronavirus, hepatitis C; metabolic disorders; heart diseases; heart failure; pathological angiogenesis, such as ocular angiogenesis or a disease or condition associated with ocular angiogenesis, such as cancer-associated neovascularization; and ocular diseases such as age-related macular degeneration and corneal neovascularization; atherosclerosis; metabolic diseases; diabetes; type I diabetes; type 2 diabetes; insulin resistance; obesity; marfan's syndrome; a Royal's syndrome; kidney disease; diastolic heart failure; fibrotic pulmonary complications of aPD1 and other CPI therapies; asthma and other interstitial lung diseases, including Hermanski-Priderac syndrome, liver diseases, such as non-alcoholic steatohepatitis or non-alcoholic fatty liver disease; uterine diseases, such as uterine fibroids and uterine or cervical fibrosis.

The invention relates to a forming technology of superfine thin walled tubular products for vessel stents in the field of treatment, specifically to a method of processing cobalt-base alloy superfine thin walled tubes for novel coronary artery stents. The method solves the problems of great difficulty in tubular product processing and low yield of tubular products in a conventional technology. The method for forming finished products comprises the successive technological processes of smelting, forging, hot rolling, hot rolling punching, honing and cleaning of inner surfaces and outer surfaces, annealing, cold rolling / drawing, annealing, and repeated cold rolling / drawing. During overall process of the repeated cold rolling, diameter reducing deformation of the tubular products should be controlled in each pass, and match relationship between the diameter reducing deformation and wall reducing deformation should be well adjusted for guaranteeing that load carrying capability of inner walls does not exceed sigma b (breaking strength) and thus for preventing horizontal microscopic breakage. With rough blanks of the tubular products being acquired in high temperature conditions and the cobalt-base alloy tubular products being acquired through rolling at a room temperature, the processing method guarantees high dimensional precision, bright and clean inner and outer surfaces and excellent mechanical property of the tubular products; and is easy to realize and has high controllability and high economic benefit.

The invention relates to an operating platform for percutaneous coronary artery stent implantation, which consists of a tainted blood tank, a cotton gauze tank, a sundries tank, a near-end thread-guiding clip, a far-end thread-guiding clip, a trapezoidal opening and a tainted blood tank cover plate.

The invention discloses a medicine for preventing and treating restenosis after coronary artery stent implantation and a preparation method thereof, which comprises the following raw materials in parts by weight: 800-1200 parts of tanshinone, 200-300 parts of hirudin, 20-30 parts of borneol, 6-9 parts of muscone are made into 1000 parts. The invention has the characteristics of good curative effect, no toxic and side effects, can reduce the incidence of restenosis after coronary artery stent implantation, obviously improve the clinical symptoms of patients, reduce the long-term thrombosis risk of patients, and the like, and has remarkable clinical curative effect. It provides a new option for preventing restenosis (ISR) after coronary stent implantation.